Bristol Myers Squibb (BMY) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Bristol Myers Squibb (NYSE: BMY) in the last few weeks:

• 2/6/2026 – Bristol Myers Squibb had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $40.00 price target on the stock.
• 2/6/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $72.00 price target on the stock, up previously from $62.00.
• 2/6/2026 – Bristol Myers Squibb had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $60.00 price target on the stock, up previously from $55.00.
• 2/6/2026 – Bristol Myers Squibb had its price target raised by analysts at Citigroup Inc. from $60.00 to $64.00. They now have a “neutral” rating on the stock.
• 1/28/2026 – Bristol Myers Squibb had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $66.00 price target on the stock, up previously from $62.00.
• 1/27/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $60.00 price target on the stock, up previously from $53.00.
• 1/13/2026 – Bristol Myers Squibb had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an “outperform” rating on the stock.
• 1/9/2026 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by analysts at Scotiabank. They now have a $60.00 price target on the stock, up previously from $53.00.
• 1/7/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $53.00 price target on the stock, up previously from $45.00.
• 1/7/2026 – Bristol Myers Squibb was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $65.00 price target on the stock, up previously from $46.00.
• 12/23/2025 – Bristol Myers Squibb had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/15/2025 – Bristol Myers Squibb was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $61.00 price target on the stock, up previously from $52.00.
• 12/12/2025 – Bristol Myers Squibb had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $37.00 price target on the stock, up previously from $36.00.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.